Close Menu

NEW YORK – Illumina and Emedgene announced on Wednesday a partnership on software for use in next-generation sequencing-based rare disease diagnosis.

Under the non-exclusive deal, the partners will integrate Emedgene's clinical rare disease application into Illumina's TruSight software suite. Financial and other terms of the agreement were not disclosed.

Emedgene, based in Palo Alto, California, offers software tools for automated genome interpretation in clinical and research use cases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

Sponsored by

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.